Io Therapeutics Phase II Clinical Stage and Preclinical Retinoid Compounds for Treatment of Cancers
Martin E. Sanders, M.D.
The highly potent and selective third generation RXR agonist compound IRX4204 is a potential treatment for normal aging-related neurodegeneration, Parkinson’s disease (PD), and Alzheimer’s disease (AD)
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D., Federation of American Societies for Experimental Biology, July 2024
IRX4204 A Phase II Clinical Stage Potent and Selective RXR Agonist Compound for Treatment of Parkinson’s Disease
Martin E. Sanders, M.D., Sichuan Provincial Neuroscience Society, 2023
IRX4204 – A Clinical Stage Potent and Selective RXR Agonist Compound for Treatment of Psoriasis and other Autoimmune Skin Diseases
Martin E. Sanders, M.D.